Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Conditions

• Neovascular Age-Related Macular Degeneration (nAMD)
• Wet AMD

Eligibility Criteria

Sex

ALL

Age

50 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ixo-vec — GENETIC
  Ixo-vec will be administered intravitreally.
• Aflibercept — DRUG
  Aflibercept will be administered intravitreally.

Study Details

This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to intravitreal aflibercept (active comparator). The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured as an average at Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.

Key Dates

Start date

Mar 16, 2026

Status verified

May 2026

Primary completion

Nov 15, 2027

Completion

Oct 20, 2031

Study Design

Enrollment

284 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Ixo-vec
  Participants will receive 3 monthly loading doses of aflibercept 2 mg IVT, a single IVT injection of Ixo-vec 6 x 10\^10 vg/eye at Week 1, and sham injections every 8 weeks.
• Active Comparator: Aflibercept
  Participants will receive 3 monthly loading doses of aflibercept 2 mg IVT, a sham injection at Week 1, and aflibercept 2 mg IVT every 8 weeks.

Primary Outcome Measure

Mean Change from Baseline in BCVA Based on an Average at Weeks 52 and 56 [ Time Frame: Baseline, Week 52 and Week 56 ]

Central Contacts

• Adverum Study Contact
  650-656-9323
  [email protected]

Locations (46)

Find similar trials in Phoenix, AZ

Related Studies

• Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
  Enrolling By Invitation · AbbVie · Phoenix, Arizona
• A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
  PHASE3 · Not Yet Recruiting · Rophibio, Inc. · Phoenix, Arizona
• Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
  PHASE3 · Recruiting · 4D Molecular Therapeutics · Scottsdale, Arizona
• Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
  PHASE3 · Not Yet Recruiting · Ocular Therapeutix, Inc. · Santa Barbara, California